Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018159900) SREBP-1 DECOY OLIGODEOXYNUCLEOTIDE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING FATTY LIVER DISEASE CONTAINING SAME AS ACTIVE INGREDIENT
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/159900 International Application No.: PCT/KR2017/006468
Publication Date: 07.09.2018 International Filing Date: 21.06.2017
IPC:
C12N 15/113 (2010.01) ,A61K 48/00 (2006.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
113
Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Applicants:
대구가톨릭대학교산학협력단 DAEGU CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION [KR/KR]; 경상북도 경산시 하양읍 하양로 13-13 13-13, Hayang-ro, Hayang-eup Gyeongsan-si Gyeongsangbuk-do 38430, KR
Inventors:
박관규 PARK, Kwan-Kyu; KR
윤성원 YOUN, Sung-Won; KR
김정연 KIM, Jung-Yeon; KR
안현진 AN, Hyun-Jin; KR
Agent:
최규환 CHOI, Kyu Whan; KR
Priority Data:
10-2017-002584728.02.2017KR
Title (EN) SREBP-1 DECOY OLIGODEOXYNUCLEOTIDE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING FATTY LIVER DISEASE CONTAINING SAME AS ACTIVE INGREDIENT
(FR) OLIGODÉSOXYNUCLÉOTIDE LEURRE DE TYPE SREBP-1 ET COMPOSITION PHARMACEUTIQUE POUR PRÉVENIR OU TRAITER UNE STÉATOSE HÉPATIQUE LE CONTENANT EN TANT QUE PRINCIPE ACTIF
(KO) SREBP-1 디코이 올리고디옥시뉴클레오티드 및 이를 유효성분으로 함유하는 지방간 질환의 예방 또는 치료용 약학 조성물
Abstract:
(EN) The present invention relates to SREBP-1 decoy oligodeoxynucleotide and a pharmaceutical composition for preventing or treating fatty liver disease containing the same as an active ingredient. More particularly, the SREBP-1 decoy oligonucleotide according to the present invention controls the expression of genes related to lipid biosynthesis by inhibiting the transcription factor activity of SREBP-1, which is a transcription factor, thereby suppressing the accumulation of fat in the liver when a fatty liver-induced animal model is treated with the SREBP-1 decoy oligodeoxynucleotide. Moreover, the SREBP-1 decoy oligonucleotide exhibits the effects of reducing blood alanine reducing, aspartate transaminase, total cholesterol, and neutral fat indices, as well as transaminase liver and blood inflammation indices. Due to such effects, the SREBP-1 decoy oligonucleotide can be used as a pharmaceutical composition for preventing or treating fatty liver disease.
(FR) La présente invention concerne un oligodésoxynucléotide leurre de type SREBP-1 et une composition pharmaceutique pour prévenir ou traiter une stéatose hépatique le contenant en tant que principe actif. Plus particulièrement, l'oligonucléotide leurre de type SREBP-1 selon la présente invention régule l'expression de gènes associés à la biosynthèse des lipides par inhibition de l'activité du facteur de transcription de SREBP-1, qui est un facteur de transcription, ce qui permet de supprimer l'accumulation de graisse dans le foie lorsqu'un modèle animal à stéatose hépatique induite est traité avec l'oligodésoxynucléotide leurre de type SREBP-1. De plus, l'oligonucléotide leurre de type SREBP-1 présente les effets de réduction de l'alanine sanguine, de l'aspartate transaminase, du cholestérol total et des indices de graisse neutre, ainsi que des indices de transaminase hépatique et de l'inflammation sanguine. Du fait de ces effets, l'oligonucléotide leurre de type SREBP-1 peut être utilisé en tant que composition pharmaceutique pour prévenir ou traiter la stéatose hépatique.
(KO) 본 발명은 SREBP-1 디코이 올리고디옥시뉴클레오티드 및 이를 유효성분으로 함유하는 지방간 질환의 예방 또는 치료용 조성물에 관한 것으로, 더욱 상세하게는 본 발명의 SREBP-1 디코이 올리고디옥시뉴클레오티드는 전사인자인 SREBP-1의 전사인자 작용을 억제하여 지질의 생합성과 관련된 유전자들의 발현을 조절함으로써, 지방간이 유도된 동물모델에 SREBP-1 디코이 올리고디옥시뉴클레오티드 처리시 간에서의 지방의 축적을 억제하고, 혈중 알라닌 아미노전이효소, 아스파르트산 아미노전이효소, 총 콜레스테롤 및 중성지방 지수가 감소하며, 간 및 혈중 염증 지수 또한 감소하는 효과를 나타내며, 이러한 효과로 인하여 SREBP-1 디코이 올리고디옥시뉴클레오티드는 지방간 질환의 예방 또는 치료용 약학 조성물로 이용 가능하다.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Korean (KO)
Filing Language: Korean (KO)